HELP fails the engine's quality floor (1.2 vs. 4.0) on negative FCF and a weak Piotroski score, and its analyst target was flagged as implausible and rejected — consistent with the exit-position action note — while an overbought technical bounce and a binary earnings report in 12 days add near-term event risk.
Thesis pillars
- Implausible Analyst Target Flag—
- Cash Burn Quality Floor Breach—
- Overbought Recovery Bounce—
- +1 more pillar — see the Why tab for full reasoning
Cybin Inc. (HELP) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $7.95: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.4/10. Specifically: Elevated put/call ratio: 3.00; Below-average business quality.
Cybin Inc., doing business as Helus Pharma, a clinical stage pharmaceutical company, focuses on developing therapies to treat various psychiatric and neurological conditions.It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major... Read more
Sell if holding. Engine safety override at $7.95: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.4/10. Specifically: Elevated put/call ratio: 3.00; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 4.4/10, moderate confidence.
Passes 6/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on earnings proximity 5d<=7d. Suitability: speculative.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Quality below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $7.95: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.4/10. Specifically: Elevated put/call ratio: 3.00; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $7.27. Score 4.4/10, moderate confidence.
Take-profit target: $8.28 (+5.9% upside). Prior stop was $7.27. Stop-loss: $7.27.
DATA_ISSUE: analyst_target_implausible (raw $35.35 vs price $7.82 — ratio 4.5×). Rejected, falling back to technical TP.; Quality below floor (1.2 < 4.0).
Cybin Inc. trades at a P/E of N/A (forward -4.0). TrendMatrix value score: 5.0/10. Verdict: Sell.
8 analysts cover HELP with a consensus score of 4.3/5. Average price target: $35.
What does Cybin Inc. do?Cybin Inc., doing business as Helus Pharma, a clinical stage pharmaceutical company, focuses on developing therapies to...
Cybin Inc., doing business as Helus Pharma, a clinical stage pharmaceutical company, focuses on developing therapies to treat various psychiatric and neurological conditions.It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and HLP004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company' preclinical product includes HLP005, a phenethylamine and tryptamine derivative to treat central nervous system. It has a strategic partnership agreement with Segal Trials to evaluating HLP003 for the adjunctive treatment of major depressive disorder; and with Osmind for mental health treatments. The company is headquartered in Toronto, Canada.